B of A Securities Maintains Neutral on Novavax, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan maintains a Neutral rating on Novavax (NASDAQ:NVAX) and raises the price target from $12 to $18.
June 14, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Alec Stranahan maintains a Neutral rating on Novavax and raises the price target from $12 to $18.
The raised price target from $12 to $18 suggests a positive outlook on Novavax's future performance, which could lead to a short-term increase in stock price. However, the Neutral rating indicates that the analyst does not see a strong buy or sell signal.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100